Why the study?
Does the routine adoption of molecular diagnosis alter the reported incidence and prevalence rates of Duchenne and Becker muscular dystrophy?
Does the routine adoption of molecular diagnosis alter the reported incidence and prevalence rates of Duchenne and Becker muscular dystrophy?
The adoption of molecular diagnosis for dystrophinopathies significantly altered epidemiological estimates, increasing BMD prevalence and decreasing DMD incidence, likely due to reduced diagnostic errors and familial recurrence.
Answers are grounded in this paper and cite their sources.
Molecular diagnosis may refine dystrophinopathy epidemiology; leaves open whether rate changes reflect improved classification or true incidence shifts.
A molecular genetics-based epidemiological investigation was carried out in 1997 in the territory of North-West Tuscany, central Italy, to calculate incidence and prevalence rates of Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). Results were compared with a previous epidemiological study conducted in the same area in 1981, in the pre-dystrophin era. Routine adoption of methods of molecular diagnosis determined an increase in prevalence of BMD from 1.06 x 10(-5) to 2.42 x 10(-5) inhabitants, while cumulative incidence of DMD was markedly decreased from 23.12 x 10(-5) during the period 1965-1976 to 10.71 x 10(-5) male live births during the period 1977 1994. The combined reduction of DMD/BMD diagnostic error rate and familial recurrence could explain these results, providing the bases for a consistent redefinition of dystrophinopathy carrier frequency in the area considered.
No takes yet. Share an insight, caveat, or question.
Siciliano et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: